NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research has been awarded C$12.6 million (US$12.7 million) from the provincial government to fund a clinical trials program that will use genomics and personalized medicine in a translational science effort, OICR said Monday.
The funding will be used to support two trials that are part of the High Impact Clinical Trials (HICT) Program over a four-year period.
One of these HICT efforts is the Genomic Cohort Study for Ontario Clinical Trials, which is a collaboration with Princess Margaret Hospital. In this study, researchers will develop standard operating procedures to help safely and effectively integrate genomics technologies with standard clinical practice and to improve patient care. The expectation is that genetic information could be used to help determine how to best match patients to the most optimal treatments to maximize the anti-tumor efficacy and to reduce side-effects.
The other clinical trial is the Rare Tumor Clinical Trials Initiative, a partnership between OICR, Pfizer Canada, and the NCIC Clinical Trials Group at Queens University. This multidisciplinary and multi-center trial will engage genomics researchers and pathologists to develop new ways to study rare tumors.